| 2.38 -0.11 (-4.42%) | 04-07 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 3.32 | 1-year : | 3.78 |
| Resists | First : | 2.84 | Second : | 3.24 |
| Pivot price | 2.47 |
|||
| Supports | First : | 2.2 | Second : | 1.83 |
| MAs | MA(5) : | 2.43 |
MA(20) : | 2.48 |
| MA(100) : | 3.18 |
MA(250) : | 4.37 |
|
| MACD | MACD : | -0.2 |
Signal : | -0.2 |
| %K %D | K(14,3) : | 26.8 |
D(3) : | 27.7 |
| RSI | RSI(14): 39.6 |
|||
| 52-week | High : | 10.27 | Low : | 2.11 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ XTLB ] has closed above bottom band by 29.1%. Bollinger Bands are 62.4% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 8 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 2.51 - 2.52 | 2.52 - 2.53 |
| Low: | 2.35 - 2.36 | 2.36 - 2.38 |
| Close: | 2.36 - 2.38 | 2.38 - 2.4 |
XTL Biopharmaceuticals Ltd., a biopharmaceutical company, engages in the acquisition and development of pharmaceutical products for the treatment of autoimmune diseases. The company's lead drug candidate is hCDR1, a Phase II-ready asset for the treatment of systemic lupus erythematosus and Sjogren's syndrome. It has a licensing agreement with Yeda Research and Development Company Limited for the research, development, and commercialization of hCDR1 for various indications. The company was formerly known as Xenograft Technologies Ltd. and changed its name to XTL Biopharmaceuticals Ltd. in July 1995. XTL Biopharmaceuticals Ltd. was incorporated in 1993 and is headquartered in Ramat Gan, Israel.
Wed, 01 Apr 2026
XTL Biopharmaceuticals Ltd. Sponsored ADR Trade Ideas — SWB:HHB0 - TradingView
Sun, 29 Mar 2026
XTLB PE Ratio & Valuation, Is XTLB Overvalued - Intellectia AI
Fri, 20 Mar 2026
XTL investors will see every 4 ADSs become 1 on March 25 - Stock Titan
Fri, 20 Mar 2026
XTL Biopharmaceuticals (NASDAQ: XTLB) sets one-for-four reverse ADS ratio change - Stock Titan
Tue, 10 Mar 2026
XTL Biopharmaceuticals Ends Acquisition Talks After NeuroNOS LOI Expires - TipRanks
Fri, 27 Feb 2026
XTL Biopharmaceuticals Limited Faces Nasdaq Delisting Following Insolvency of Subsidiary The Social Proxy - Quiver Quantitative
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 2 (M) |
| Shares Float | 275 (M) |
| Held by Insiders | 38.4 (%) |
| Held by Institutions | 3.5 (%) |
| Shares Short | 14 (K) |
| Shares Short P.Month | 16 (K) |
| EPS | -3.6 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -0 |
| Profit Margin | 0 % |
| Operating Margin | -853.6 % |
| Return on Assets (ttm) | -240.6 % |
| Return on Equity (ttm) | -577.2 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | -0.95 |
| Sales Per Share | 0.4 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | -0.67 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 5.82 |
| Price to Cash Flow | 0 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|